The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus.
A novel strain of influenza A H1N1 emerged in the spring of 2009 and has spread rapidly throughout the world. Although vaccines have recently been developed that are expected to be protective, their availability was delayed until well into the influenza season. Although anti-influenza drugs such as neuraminidase inhibitors can be effective, resistance to these drugs has already been reported. Although human saliva was known to inhibit viral infection and may thus prevent viral transmission, the components responsible for this activity on influenza virus, in particular, influenza A swine origin influenza A virus (S-OIV), have not yet been defined. By using a proteomic approach in conjunction with beads that bind alpha-2,6-sialylated glycoprotein, we determined that an alpha-2-macroglobulin (A2M) and an A2M-like protein are essential components in salivary innate immunity against hemagglutination mediated by a clinical isolate of S-OIV (San Diego/01/09 S-OIV). A model of an A2M-based "double-edged sword" on competition of alpha-2,6-sialylated glycoprotein receptors and inactivation of host proteases is proposed. We emphasize that endogenous A2M in human innate immunity functions as a natural inhibitor against S-OIV.
Chen
Chao-Hsuan
CH
Division of Dermatology, Department of Medicine, University of California, San Diego, CA 92121, USA.
Zhang
Xing-Quan
XQ
Lo
Chih-Wei
CW
Liu
Pei-Feng
PF
Liu
Yu-Tsueng
YT
Gallo
Richard L
RL
Hsieh
Ming-Fa
MF
Schooley
Robert T
RT
Huang
Chun-Ming
CM
D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology*; D008962:Models, Theoretical; D012463:Saliva / Q000276:immunology*; D000511:alpha-Macroglobulins / Q000276:immunology*
D006023:Glycoproteins; D000511:alpha-Macroglobulins
J Biol Chem. 1989 Jun 15;264(17):9850-8
2470765
Virology. 1983 Jun;127(2):361-73
6868370
Acta Pathol Microbiol Scand. 1965;64:224-8
14329861
J Virol. 2009 Apr;83(8):3754-61
19211766
Virology. 1983 Dec;131(2):394-408
6197808
Proteomics Clin Appl. 2008 Sep;2(9):1234-45
21136919
Nat Rev Microbiol. 2006 Jul;4(7):529-36
16778838
Am J Respir Crit Care Med. 2003 Jul 15;168(2):199-207
12689849
Clin Chim Acta. 1987 Jun 15;165(2-3):277-88
2443279
Virology. 1997 Jan 20;227(2):493-9
9018149
Proteomics. 2003 Oct;3(10):1980-7
14625860
Protein Expr Purif. 2008 Jan;57(1):72-80
18029197
Proteomics. 2008 Aug;8(16):3406-15
18651708
J Immunol. 1949 Nov;63(3):261-71
15393958
Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1066-76
12871854
Nat Biotechnol. 2009 Sep;27(9):797-9
19741625
J Clin Microbiol. 2009 Sep;47(9):3060-1
19605579
Virology. 1975 Dec;68(2):440-54
128196
Virology. 1974 Oct;61(2):397-410
4472498
Arch Oral Biol. 1995 Dec;40(12):1151-5
8850655
Oral Microbiol Immunol. 2009 Feb;24(1):18-24
19121065
J Gen Virol. 1969 Jul;5(1):141-3
5823666
Virology. 1975 Dec;68(2):426-39
173078
Trends Microbiol. 1994 Feb;2(2):39-43
8162439
Virology. 1999 May 25;258(1):1-20
10329563
In Vitro Cell Dev Biol. 1991 Mar;27A(3 Pt 1):183-4
2033016
Acta Pathol Microbiol Scand. 1965;63:291-8
14301676
Proc Soc Exp Biol Med. 1948 Nov;69(2):291-4
18102207
Ann Acad Med Stetin. 2006;52(2):33-7; discussion 37
17633124
Cell. 2009 Dec 24;139(7):1243-54
20064371
J Biol Chem. 2006 Mar 3;281(9):5780-9
16298998
FASEB J. 1992 Dec;6(15):3345-53
1281457
J Biol Chem. 1989 Jun 15;264(17):9842-9
2470764
Swiss Med Wkly. 2008 Apr 5;138(13-14):191-6
18389391
Proteomics Clin Appl. 2009 Jul 1;3(7):810-820
20011683
Pneumonol Alergol Pol. 2005;73(1):12-7
16539178